Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2026-04-15EMA Withdrawn: Bortezomib Hospira (bortezomib) — Pfizer Europe MA EEIG
The EMA has withdrawn the European marketing authorization for Bortezomib Hospira (bortezomib) by Pfizer Europe MA EEIG, affecting treatment…
-
CLINICAL_TRIALS withdrawal · 2026-04-15Clinical Trial Update: Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 1]
A Phase 1 trial of Selvigaltin in combination with standard of care for relapsed/refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-01-14Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 1]
The Phase 1 trial evaluating intravenous TAK-573 in combination therapy for relapsed or refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-01-06Clinical Trial Update: Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells [Phase 1, Phase 2]
A Phase 1/Phase 2 study evaluating immune reconstitution monitoring and pneumococcal vaccination in patients treated with CAR-T cells has be…
-
CLINICAL_TRIALS withdrawal · 2025-12-04Clinical Trial Update: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function [Phase 1]
A Phase 1 study evaluating belantamab mafodotin in multiple myeloma patients with varying hepatic function has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2025-11-27EMA Lapsed: Celdoxome pegylated liposomal (doxorubicin hydrochloride) — Baxter Holding B.V.
EMA notes that the marketing authorization for Celdoxome pegylated liposomal doxorubicin hydrochloride has lapsed, covering breast cancer, o…
-
CLINICAL_TRIALS withdrawal · 2025-10-21Clinical Trial Update: Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma [Phase 2]
This clinical trial update reports the termination of a Phase 2 salvage therapy trial using daratumumab, ixazomib, pomalidomide, and dexamet…
-
CLINICAL_TRIALS withdrawal · 2025-10-15Clinical Trial Update: Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma [Phase 1]
A Phase 1 trial of bendamustine hydrochloride in previously treated multiple myeloma and plasma cell leukemia has been withdrawn.
-
EMA withdrawal · 2025-10-06EMA Application withdrawn: Aplidin (plitidepsin) — Pharma Mar S.A.
The EMA has withdrawn the marketing authorization application for Aplidin (plitidepsin) by Pharma Mar S.A. for the treatment of multiple mye…
-
CLINICAL_TRIALS withdrawal · 2025-08-15Clinical Trial Update: A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma [Phase 3]
A Phase 3 trial comparing talquetamab to belantamab mafodotin in relapsed/refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-07-03Clinical Trial Update: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL [Phase 1]
The Phase 1 study of BMF-219, Biomea Fusion's covalent menin inhibitor, in adults with AML, ALL, DLBCL, multiple myeloma, and CLL/SLL has be…
-
CLINICAL_TRIALS withdrawal · 2025-06-13Clinical Trial Update: Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma
The IND expanded access program for Janssen's CAR-T therapy for multiple myeloma is no longer available.
-
CLINICAL_TRIALS withdrawal · 2025-05-18Clinical Trial Update: Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease [Phase 2]
A Phase 2 trial evaluating high-dose intravenous ascorbic acid in measurable solid tumors has been withdrawn, sponsored by Situs Cancer Rese…
-
CLINICAL_TRIALS withdrawal · 2025-04-01Clinical Trial Update: Melflufen for Elderly Patients With Relapsed Myeloma [Phase 2]
A Phase 2 trial of Melflufen in elderly patients with relapsed multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-03-03Clinical Trial Update: Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM [Phase 2]
A Phase 2 trial evaluating siltuximab to prevent cytokine release syndrome in patients with relapsed/refractory multiple myeloma treated wit…
-
EMA withdrawal · 2025-02-19EMA Expired: Blenrep (belantamab mafodotin) — GlaxoSmithKline Trading Services Limited
The EMA has expired the marketing authorization for Blenrep (belantamab mafodotin) held by GlaxoSmithKline Trading Services Limited, with th…
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: Multiple Myeloma Patient Registry
A Janssen-sponsored Multiple Myeloma patient registry has been terminated.
-
CLINICAL_TRIALS withdrawal · 2025-01-31Clinical Trial Update: A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors [Phase 1]
A Phase I trial evaluated the tolerability of 225Ac-DOTATATE in patients with refractory or relapsed multiple myeloma expressing somatostati…
-
CLINICAL_TRIALS withdrawal · 2025-01-17Clinical Trial Update: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 trial of ISB 1442 for relapsed/refractory multiple myeloma has been terminated.
-
CLINICAL_TRIALS withdrawal · 2024-11-25Clinical Trial Update: Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
A Travera Inc clinical trial (NCT04985357) evaluating mass response as a biomarker for tumor sensitivity to drugs has been withdrawn; no res…
-
CLINICAL_TRIALS withdrawal · 2024-11-19Clinical Trial Update: Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 trial of mezigdomide plus ixazomib and dexamethasone for relapsed and refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-10-03Clinical Trial Update: B-Cell Hematologic Malignancy Vaccination Registry
A clinical trial update indicates that the B-cell hematologic malignancy vaccination registry (NCT02298816) sponsored by Wake Forest Univers…
-
CLINICAL_TRIALS withdrawal · 2024-09-05Clinical Trial Update: 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy [Phase 2]
A Phase II randomized, open-label study evaluating an anti-SLAM monoclonal antibody as maintenance therapy in multiple myeloma has been with…
-
CLINICAL_TRIALS withdrawal · 2024-09-05Clinical Trial Update: A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma [Phase 1]
This clinical trial update indicates that Taiho Oncology’s Phase 1 dose-finding study followed by a safety and efficacy study in patients wi…
-
CLINICAL_TRIALS withdrawal · 2024-07-16Clinical Trial Update: Marizomib Central Nervous System (CNS) [Phase 2]
A Phase 2 trial of marizomib for multiple myeloma (including relapsed disease) has been withdrawn.